Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Intra-Abdominal Anaerobic Infections: Bacteriology and Therapeutic Potential of Newer Antimicrobial Carbapenem, Fluoroquinolone, and Desfluoroquinolone Therapeutic Agents

Ellie J. C. Goldstein
Clinical Infectious Diseases
Vol. 35, Supplement 1. 2001: An Anaerobe Odyssey: A Celebration of Dr. Sydney M. Finegold's 80th Birthday (Sep. 1, 2002), pp. S106-S111
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4462171
Page Count: 6
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Intra-Abdominal Anaerobic Infections: Bacteriology and Therapeutic Potential of Newer Antimicrobial Carbapenem, Fluoroquinolone, and Desfluoroquinolone Therapeutic Agents
Preview not available

Abstract

Intra-abdominal infections are biphasic, synergistic processes with early peritonitis and bacteremia due to aerobes and a later abscess component due to anaerobes. Although Bacteroides fragilis is the most commonly recognized pathogen, other anaerobes, including other members of the B. fragilis-group species, are major components of infection. Anaerobic bacteremia is often associated with an intra-abdominal source. New antimicrobial agents with anaerobic activity are in various stages of development for the therapy of intra-abdominal infections. The in vitro activity and the currently available sparse clinical data are reviewed for a new carbapenem (ertapenem), several fluoroquinolones (trovafloxacin, moxifloxacin, and gemifloxacin), and a desfluoroquinolone (BMS-284756).

Page Thumbnails

  • Thumbnail: Page 
S106
    S106
  • Thumbnail: Page 
S107
    S107
  • Thumbnail: Page 
S108
    S108
  • Thumbnail: Page 
S109
    S109
  • Thumbnail: Page 
S110
    S110
  • Thumbnail: Page 
S111
    S111